A detailed history of Bell Bank transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Bell Bank holds 112,641 shares of GILD stock, worth $10.4 Million. This represents 1.13% of its overall portfolio holdings.

Number of Shares
112,641
Previous 132,473 14.97%
Holding current value
$10.4 Million
Previous $9.09 Million 3.88%
% of portfolio
1.13%
Previous 0.77%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 05, 2024

SELL
$66.59 - $83.99 $1.32 Million - $1.67 Million
-19,832 Reduced 14.97%
112,641 $9.44 Million
Q2 2024

Jul 31, 2024

BUY
$63.15 - $72.88 $266,619 - $307,699
4,222 Added 3.29%
132,473 $9.09 Million
Q1 2024

Apr 23, 2024

BUY
$71.58 - $87.29 $330,556 - $403,105
4,618 Added 3.74%
128,251 $9.39 Million
Q4 2023

Jan 22, 2024

SELL
$73.27 - $83.09 $31,799 - $36,061
-434 Reduced 0.35%
123,633 $10 Million
Q3 2023

Oct 30, 2023

BUY
$73.94 - $80.67 $57,821 - $63,083
782 Added 0.63%
124,067 $9.3 Million
Q2 2023

Jul 26, 2023

SELL
$76.01 - $86.7 $355,118 - $405,062
-4,672 Reduced 3.65%
123,285 $9.5 Million
Q1 2023

Apr 19, 2023

SELL
$77.31 - $88.08 $694,475 - $791,222
-8,983 Reduced 6.56%
127,957 $10.6 Million
Q4 2022

Jan 31, 2023

SELL
$62.32 - $89.47 $448,143 - $643,378
-7,191 Reduced 4.99%
136,940 $11.8 Million
Q3 2022

Oct 11, 2022

BUY
$59.54 - $68.01 $995,389 - $1.14 Million
16,718 Added 13.12%
144,131 $8.89 Million
Q2 2022

Jul 15, 2022

BUY
$57.72 - $65.01 $603,578 - $679,809
10,457 Added 8.94%
127,413 $7.88 Million
Q1 2022

Apr 25, 2022

BUY
$57.92 - $72.58 $6.77 Million - $8.49 Million
116,956 New
116,956 $6.95 Million
Q2 2020

Aug 13, 2020

SELL
$72.34 - $84.0 $1.45 Million - $1.68 Million
-20,040 Closed
0 $0
Q1 2020

May 11, 2020

BUY
$62.63 - $80.22 $1.26 Million - $1.61 Million
20,040 New
20,040 $1.5 Million

Others Institutions Holding GILD

About GILEAD SCIENCES, INC.


  • Ticker GILD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,253,369,984
  • Market Cap $116B
  • Description
  • Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...
More about GILD
Track This Portfolio

Track Bell Bank Portfolio

Follow Bell Bank and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bell Bank, based on Form 13F filings with the SEC.

News

Stay updated on Bell Bank with notifications on news.